Ocular Therapeutix, Inc. (OCUL)
| Market Cap | 1.32B -45.0% |
| Revenue (ttm) | 50.38M -9.7% |
| Net Income | -326.81M |
| EPS | -1.46 |
| Shares Out | 220.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,296,597 |
| Open | 5.98 |
| Previous Close | 6.01 |
| Day's Range | 5.81 - 6.27 |
| 52-Week Range | 5.81 - 16.44 |
| Beta | 1.22 |
| Analysts | Strong Buy |
| Price Target | 25.73 (+327.41%) |
| Earnings Date | Nov 9, 2026 |
About OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of ... [Read more]
Financial Performance
In 2025, Ocular Therapeutix's revenue was $51.95 million, a decrease of -18.47% compared to the previous year's $63.72 million. Losses were -$265.94 million, 37.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for OCUL stock is "Strong Buy." The 12-month stock price target is $25.73, which is an increase of 327.41% from the latest price.
News
Ocular Therapeutix Transcript: UBS Global Biopharma Conference 2026
SOL-1 showed superiority to EYLEA with p<0.0006, supporting a Q4 2026 NDA for AXPAXLI. SOL-R changes aim to preserve trial integrity and assess longer-term commercial differentiation; HELIOS-3 enrollment is progressing well.
Ocular Therapeutix price target raised to $28 from $25 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Ocular Therapeutix (OCUL) to $28 from $25 and keeps a Buy rating on the shares following the Q3 report. Published first on…
Ocular Therapeutix Earnings Call Transcript: Q3 2026
AXPAXLI's SOL-1 superiority and durability support a planned Q4 2026 wet AMD NDA; SOL-R's endpoint change aims to preserve trial integrity. Q3 cash was $530.6 million, with runway into 2028 excluding full commercialization expenses.
Ocular Therapeutix Earnings release: Q3 2026
Ocular Therapeutix released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Ocular Therapeutix Quarterly report: Q3 2026
Ocular Therapeutix has published its Q3 2026 quarterly earnings report on November 9, 2026.
Ocular Therapeutix reports Q3 EPS (42c), consensus (35c)
Reports Q3 revenue $12.87M, consensus $14.3M. “2026 has been a transformational year for Ocular Therapeutix (OCUL) and we are in a strong position as we prepare to submit our NDA…
Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights
AXPAXLI™ NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 safety analysis Several FDA interactions, including most recent September 2026 Pre-NDA Meeting, reaffi...
Ocular Therapeutix Slides: OSN New York & Retina presentation
Ocular Therapeutix has posted slides in relation to its latest quarterly earnings report, which was published on November 7, 2026.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experie...
Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026
BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announ...
Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences
BEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announ...
Ocular Therapeutix management to meet with Piper Sandler
Meeting to be held in New York on October 21 hosted by Piper Sandler.
Ocular Therapeutix Transcript: Chardan's 10th Annual Healthcare Conference
SOL-1 showed superiority versus an anti-VEGF, and the Q4 2026 NDA submission remained on schedule after FDA meetings. AXPAXLI is positioned as a maintenance therapy, with SOL-1’s amended topline now expected in Q1 2028.
Ocular Therapeutix Slides: Investor presentation
Ocular Therapeutix has posted slides in relation to its latest quarterly earnings report, which was published on October 15, 2026.
Ocular Therapeutix initiated with a Buy at UBS
UBS initiated coverage of Ocular Therapeutix (OCUL) with a Buy rating and $14 price target The company’s lead asset Axpaxli is a “differentiated” long-acting retinal therapy with the potential to…
Ocular Therapeutix Slides: Investor presentation
Ocular Therapeutix has posted slides in relation to its latest quarterly earnings report, which was published on October 2, 2026.
Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences
BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announ...
Ocular Therapeutix falls -18.2%
Ocular Therapeutix (OCUL) is down -18.2%, or -$1.76 to $7.89.
Ocular Therapeutix shares down 22% after 4D Molecular announces Phase 3 results
Shares of Ocular Therapeutix (OCUL) are down 22% to $7.53 in morning trading after competitor 4D Molecular Therapeutics (FDMT) announced Phase 3 clinical data for its wet age-related macular degenerat...
Ocular Therapeutix falls -18.1%
Ocular Therapeutix (OCUL) is down -18.1%, or -$1.75 to $7.90.
Ocular Therapeutix management to meet with Piper Sandler
Meeting to be held on September 27-October 1 hosted by Piper Sandler.
Ocular Therapeutix Transcript: 2026 Global Healthcare Conference
The session highlighted progress toward a 2027 launch for AXPAXLI, with a planned NDA submission in Q4 and strong FDA alignment. SOL-1 data showed clear superiority over EYLEA, and commercial readiness is high. Expansion into diabetic retinopathy offers significant growth potential.
Ocular Therapeutix completes pre-NDA meeting with FDA for Axpaxli
Ocular Therapeutix (OCUL) announced the completion of its pre-new drug application, or NDA, meeting with the FDA for its investigational product candidate Axpaxli for the treatment of wet age-related ...
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular's plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAX...
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today annou...